Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial-Reference-Cited by-同舟云学术

Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial

Published:2024-03 Issue:10432 Volume:403 Page:1141-1152
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Lanzetta Paolo,Korobelnik Jean-François,Heier Jeffrey S,Leal Sergio,Holz Frank G,Clark W Lloyd,Eichenbaum David,Iida Tomohiro,Xiaodong Sun,Berliner Alyson J,Schulze Andrea,Schmelter Thomas,Schmidt-Ott Ursula,Zhang Xin,Vitti Robert,Chu Karen W,Reed Kimberly,Rao Rohini,Bhore Rafia,Cheng Yenchieh,Sun Wei,Hirshberg Boaz,Yancopoulos George D,Wong Tien Y

Funder

Bayer AG

Publisher

Elsevier BV

Reference27 articles.

1. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis;Wong;Lancet Glob Health,2014

3. VEGFR1 signaling in retinal angiogenesis and microinflammation;Uemura;Prog Retin Eye Res,2021

4. Aflibercept in wet AMD: specific role and optimal use;Semeraro;Drug Des Devel Ther,2013

5. Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials;Jaffe;Ophthalmology,2019

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe Intraocular Inflammation After Intravitreal Injection of Faricimab: A Single-Site Case Series of Six Patients;American Journal of Ophthalmology;2025-01

2. Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration;Survey of Ophthalmology;2024-11

3. Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases;Eye;2024-08-31

4. High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab;Ophthalmology and Therapy;2024-08-30

5. Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration;Japanese Journal of Ophthalmology;2024-08-20